<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="111695">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01649869</url>
  </required_header>
  <id_info>
    <org_study_id>DMID 11-0069</org_study_id>
    <nct_id>NCT01649869</nct_id>
  </id_info>
  <brief_title>Congenital CMV and Hearing Loss in Children up to 4 Years of Age: Treating With Valganciclovir Therapy</brief_title>
  <official_title>A Phase II Randomized and Controlled Investigation of Six Weeks of Oral Valganciclovir Therapy in Infants and Children With Congenital Cytomegalovirus Infection and Hearing Loss</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Valganciclovir is a mono-valyl ester pro-drug of ganciclovir, which is rapidly converted to
      ganciclovir on absorption. Valganciclovir is approved for the treatment of Cytomegalovirus
      (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS), and for the
      prevention of CMV disease in kidney, heart, and kidney-pancreas high-risk transplant
      patients. The formulation used in this study will be valganciclovir oral solution which is
      commercially available. It will be provided as a 12g powder containing 5g valganciclovir
      free base. The oral solution formulation comprises the following excipients: Providone K30,
      fumaric acid, sodium benzoate, sodium saccharin, mannitol, flavor, and purified water. The
      valganciclovir oral solution formulation does not contain lactose anhydrous.

      The placebo comparator will be commercially available Simple Syrup (Syrup NF) as 60-90%
      sucrose in purified water.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Upon enrollment, defined as informed consent signed and confirmed eligibility, study
      subjects will be randomized, when diagnosis of congenital CMV is confirmed, to six weeks of
      oral valganciclovir or six weeks of oral placebo. Study subjects will be stratified
      according to age at randomization (1 through 11 months, 12 through 23 months, 24 through35
      months, and greater than or equal to 36 months)and according to country of enrollment (U.S.
      or U.K.). The sample size of randomized evaluable subjects is 54. Dropouts and subjects with
      audiology assessments that are inadequate for study comparison will be replaced (up to 20%,
      or n=10). During the six week treatment period, study subjects will be followed every 2
      weeks. Subjects will also be seen at approximately one month following the final dose (Study
      Day 70), and again at Study Months 4 and 6.

      At each of the visits during the treatment phase (Study Days 1, 14, 28, and 42), safety labs
      will be assessed; viral load specimens from blood, urine, and saliva will be obtained;
      adverse events will be assessed; and concurrent medications will be recorded. Ganciclovir
      concentrations for population pharmacokinetic assessment will be obtained at each study
      visit while the subject is receiving study medication. Dose adjustments for weight change
      will occur at study visits during the subject's treatment period, and may also occur at any
      time during the treatment period as indicated per protocol for neutropenia,
      thrombocytopenia, or renal impairment. At the Study Day 70 visit, safety labs will be
      obtained; viral load specimens from blood, urine, and saliva will be obtained; and adverse
      events will be assessed. Hearing will be assessed at baseline and at Study Month 6.

      Changes in whole blood viral load measurements will be correlated with hearing outcomes. In
      study subjects with increasing whole blood viral loads during the course of treatment,
      antiviral resistance may be evaluated. A Data and Safety Monitoring Board (DSMB) will be
      established to oversee the accrual, performance, safety, and efficacy of the trial.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">May 2017</completion_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of children whose change in total ear hearing assessments (improved + no change versus other)</measure>
    <time_frame>Baseline to 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion of children who have change in best ear hearing assessments [improved + no change (normal to normal) versus other; and worse versus other]</measure>
    <time_frame>Baseline to Study Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The quantitative log reduction in viruria</measure>
    <time_frame>Baseline to end of 6 weeks of therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of children who have viremia</measure>
    <time_frame>6 weeks and six months after trial entry</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The quantitative log reduction in viremia</measure>
    <time_frame>Baseline to end of 6 weeks of therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of children who have CMV detected in saliva by PCR</measure>
    <time_frame>6 weeks and six months after trial entry</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The quantitative log reduction in CMV viral load in saliva</measure>
    <time_frame>Baseline to end of 6 weeks of therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of children whose sensorineural hearing improves or remains unchanged from baseline when measured</measure>
    <time_frame>Baseline to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The correlation of change in viral load with change in total ear and best ear hearing</measure>
    <time_frame>Baseline to 6 weeks of therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in total ear hearing assessments (improved versus other).</measure>
    <time_frame>Baseline to Study Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of children who have CMV viruria detected by PCR</measure>
    <time_frame>6 weeks and 6 months after trial entry</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of unanticipated medically attended visits</measure>
    <time_frame>Study Day 1 through 2 weeks following last dose of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events which lead to permanent discontinuation of valganciclovir therapy or have an unresolved outcome</measure>
    <time_frame>baseline through day 42</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Congenital Cytomegalovirus</condition>
  <condition>Hearing Loss</condition>
  <arm_group>
    <arm_group_label>Valganciclovir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valcyte (Valganciclovir hydrochloride) Powder for oral solution</intervention_name>
    <description>Valganciclovir will be administered at 16mg/kg body weight twice daily</description>
    <arm_group_label>Valganciclovir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The placebo comparator will be commercially available Simple Syrup as 60-90% sucrose.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent from parent(s) or legal guardian(s)

          -  Sensorineural hearing loss (≥ 21dB in one or both ears, documented within 12 weeks
             prior to study entry)

          -  Children from 1 month through 3 years of age (up to the 4th birthday)

          -  CMV shedding in urine by PCR or culture (including shell vial) within 12 weeks prior
             to study enrollment

        Exclusion Criteria:•Imminent demise

          -  Imminent demise

          -  Profound sensorineural hearing loss (&gt; 90dB) in both ears

          -  Patients receiving other antiviral agents or immune globulin

          -  Gastrointestinal abnormality which might preclude absorption of an oral medication
             (e.g., a history of necrotizing enterocolitis)

          -  Documented renal insufficiency, as noted by a creatinine clearance &lt; 10 mL/min/1.73m2
             at time of study enrollment

          -  Breastfeeding from mother who is receiving ganciclovir, valganciclovir, foscarnet,
             cidofovir, or maribavir

          -  Infants known to be born to women who are HIV positive (but HIV testing is not
             required for study entry).

          -  Current receipt of other investigational drugs

          -  Previous receipt of ganciclovir or valganciclovir

          -  Known hypersensitivity to ganciclovir, valganciclovir, or components of the product

          -  Inability to attend follow-up hearing and clinical assessments

          -  Infants with Auditory neuropathy/dyssynchrony.

          -  Children with another known etiology for SNHL (e.g. connexin 26, syndrome or
             metabolic disorder associated with SNHL, inner ear malformation and widened
             vestibular aqueducts, meningitis). Exclusion of each of these conditions is not
             required for trial enrollment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>48 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David W Kimberlin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Richard Whitley, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bari Cotton, RN</last_name>
    <phone>205-934-2424</phone>
    <email>bcotton@peds.uab.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Penelope M Jester, RN MPH</last_name>
    <phone>205-934-2424</phone>
    <email>pjester@peds.uab.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David W Kimberlin, M.D.</last_name>
      <phone>205-934-5316</phone>
      <email>Dkimberlin@peds.uab.edu</email>
    </contact>
    <investigator>
      <last_name>David W Kimberlin, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roberta L DeBiasi, MD</last_name>
      <phone>202-476-5051</phone>
      <email>rdebiasi@cnmc.org</email>
    </contact>
    <investigator>
      <last_name>Roberta L DeBiasi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Medical Institutions</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ravit Boger, MD</last_name>
      <phone>410-614-3917</phone>
      <email>boger@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Ravit Boger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University in St Louis School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregory Storch, M.D.</last_name>
      <phone>314-454-6079</phone>
      <email>storch_G@kids.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Gregory Storch, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Steven &amp; Alexandra Cohen Children's Medical Center of New York (CCMC)</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sunil Sood, MD</last_name>
      <phone>516-562-3957</phone>
      <email>sood@lij.edu</email>
    </contact>
    <investigator>
      <last_name>Sunil Sood, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Caserta, M.D.</last_name>
      <phone>585-275-5944</phone>
      <email>mary_caserta@urmc.rochester.edu</email>
    </contact>
    <investigator>
      <last_name>Mary Caserta, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carolinas Medical Center - Charlotte</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amina Ahmed, M.D.B.S.</last_name>
      <phone>704-381-6870</phone>
      <email>Amina.ahmed@carolinashealthcare.org</email>
    </contact>
    <investigator>
      <last_name>Amina Ahmed, M.D.B.S.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nationwide Childrens Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205-2664</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pablo Sanchez, MD</last_name>
      <phone>614-355-5724</phone>
      <email>pablo.sanchez@nationwidechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Pablo Sanchez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Penelope Dennehy, MD</last_name>
      <phone>401-444-8360</phone>
      <email>pdennehy@lifespan.org</email>
    </contact>
    <investigator>
      <last_name>Penelope Dennehy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah School of Medicine</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kwabena Ampofo, MD</last_name>
      <phone>801-581-6791</phone>
      <email>krow.ampofo@hsc.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Kwabena Ampofo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Heart of England NHS Foundation Trust</name>
      <address>
        <city>Birmingham</city>
        <state>England</state>
        <zip>B9 5SS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Scott Hackett, BSc, MD, MB ChB, MRCP, DTM&amp;H</last_name>
      <phone>+44 121 424 2696</phone>
      <email>scott.hackett@heartofengland.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Scott Hackett, BSc, MD, MB ChB, MRCP, DTM&amp;H</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals Bristol NHS Foundation Trust</name>
      <address>
        <city>Bristal</city>
        <state>England</state>
        <zip>BS2 8AE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jolanta Bernatoniene</last_name>
      <phone>44 (0) 117 342 0172</phone>
      <email>cdxjb@bristol.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Jolanta Bernatoniene</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Free London NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>NW3 2PF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paul Griffiths, M.D.</last_name>
      <phone>020-7830-2997</phone>
      <email>pgriffiths@ucl.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Paul Griffiths, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Newcastle Upon Tyne Hospitals NHS Foundation Trust</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <state>England</state>
        <zip>NE4 6BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie Hambleton</last_name>
      <phone>0 191 256 3765</phone>
      <email>sophie.hambleton@newcastle.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Sophie Hambleton</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Southampton NHS Foundation Trust</name>
      <address>
        <city>Southampton</city>
        <state>Hampshire</state>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Saul N Faust</last_name>
      <phone>023 8079 4989</phone>
      <email>s.faust@soton.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Saul N Faust</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. George's Healthcare NHS Trust</name>
      <address>
        <city>Tooting</city>
        <state>London</state>
        <zip>SW17 0QT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mike Sharland, MBBS MD</last_name>
      <phone>+44 20 8725 3262</phone>
      <email>mike.sharland@stgeorges.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Mike Sharland, MBBS MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oxford University Hospitals NHS Trust</name>
      <address>
        <city>Oxford</city>
        <state>Oxfordshire</state>
        <zip>OX3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominic Kelly</last_name>
      <phone>44 (0) 1865 231693</phone>
      <email>dominic.kelly@paediatrics.ox.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Dominic Kelly</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Great Ormond Street Hospital</name>
      <address>
        <city>London</city>
        <zip>WC1N 3JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nigel Klein, MD</last_name>
      <phone>44(0)207-905-2891</phone>
      <email>n.klein@ucl.ac.uik</email>
    </contact>
    <investigator>
      <last_name>Nigel Klein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <lastchanged_date>September 10, 2016</lastchanged_date>
  <firstreceived_date>July 20, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>David Kimberlin, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hearing Loss</mesh_term>
    <mesh_term>Deafness</mesh_term>
    <mesh_term>Cytomegalovirus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Valganciclovir</mesh_term>
    <mesh_term>Ganciclovir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
